Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
Mesothelioma and Radical Surgery Trial
3 other identifiers
interventional
670
1 country
17
Brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without surgery and radiation therapy in treating mesothelioma. PURPOSE: This randomized clinical trial is studying combination chemotherapy, surgery, and radiation therapy to see how well they work compared to combination chemotherapy alone in treating patients with mesothelioma that can be removed by surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 11, 2005
CompletedFirst Posted
Study publicly available on registry
November 15, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedJuly 14, 2009
July 1, 2009
6.1 years
November 11, 2005
July 11, 2009
Conditions
Keywords
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (17)
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, B15 2TH, United Kingdom
Birmingham Heartlands Hospital
Birmingham, England, B9 5SS, United Kingdom
Bristol Royal Infirmary
Bristol, England, BS2 8HW, United Kingdom
Queen's Hospital
Burton-on-Trent, England, DE13 0RB, United Kingdom
Addenbrooke's Hospital
Cambridge, England, CB2 2QQ, United Kingdom
Papworth Hospital
Cambridge, England, CB3 8RE, United Kingdom
Ipswich Hospital
Ipswich, England, IP4 5PD, United Kingdom
Cookridge Hospital
Leeds, England, LS16 6QB, United Kingdom
Leicester Royal Infirmary
Leicester, England, LE1 5WW, United Kingdom
Glenfield Hospital
Leicester, England, LE3 9QP, United Kingdom
St. Thomas' Hospital
London, England, SE1 9RT, United Kingdom
Royal Marsden - London
London, England, SW3 6JJ, United Kingdom
Nottingham City Hospital NHS Trust
Nottingham, England, NG5 1PB, United Kingdom
Berkshire Cancer Centre at Royal Berkshire Hospital
Reading, England, RG1 5AN, United Kingdom
Cancer Research Centre at Weston Park Hospital
Sheffield, England, S1O 2SJ, United Kingdom
Institute of Cancer Research - Sutton
Sutton, England, SM2 5NG, United Kingdom
Royal Marsden - Surrey
Sutton, England, SM2 5PT, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Clare Peckitt
Institute of Cancer Research, United Kingdom
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 11, 2005
First Posted
November 15, 2005
Study Start
May 1, 2005
Primary Completion
June 1, 2011
Last Updated
July 14, 2009
Record last verified: 2009-07